3.67Open3.67Pre Close0 Volume10 Open Interest90.00Strike Price0.00Turnover331.74%IV65.88%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry3.67Extrinsic Value100Contract SizeAmericanOptions Type-0.0371Delta0.0004Gamma68.94Leverage Ratio-0.4173Theta-0.0057Rho-2.56Eff Leverage0.0451Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet